|
Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | Veränd. 1. Jan. | ||
| 24.58 CHF | -2.87% |
|
-18.26% | +4.19% |
| 07.01. | EA Pharma startet späte Phase-Studie zum Schizophrenie-Medikament von Newron Pharmaceuticals in Japan | MT |
| 07.01. | Newron-Partner EA Pharma startet zulassungsrelevante Studie mit Evenamide | AW |
Hauptkonkurrenten
| % | % 5 Tage | Veränd. 1 Monat | Veränd. 3 Monate | % 1. Jan. | % 1 Jahr | Veränd. 3 Jahre | Veränd. 5 Jahre | Veränd. 10 Jahre | Kap.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -2.87% | -18.26% | +23.63% | +76.49% | +4.19% | +176.42% | +922.63% | +1’004.44% | +2.26% | 631 Mio. | |
| -1.08% | +0.90% | +7.63% | +1.90% | +3.87% | +1.97% | +11.23% | -4.15% | +276.92% | 49.36 Mrd. | |
| -0.40% | -0.62% | +8.67% | +17.09% | +6.88% | +21.88% | +8.74% | +27.49% | +280.22% | 41.09 Mrd. | |
| +0.66% | +0.49% | +11.58% | +6.77% | +11.76% | +65.36% | +26.85% | -4.81% | - | 37.43 Mrd. | |
| -0.71% | -1.88% | +11.29% | +22.08% | +15.47% | +20.29% | +35.05% | -26.41% | +185.54% | 31.37 Mrd. | |
| +0.45% | +4.48% | +59.82% | +149.51% | +55.62% | +210.66% | +352.72% | +188.47% | - | 23.83 Mrd. | |
| +2.71% | -34.48% | +79.64% | +67.13% | +42.86% | +23’559.38% | +3’942.60% | - | - | 14.86 Mrd. | |
| +0.51% | +5.08% | +11.90% | +19.95% | +11.32% | +85.62% | +173.47% | +342.94% | - | 17.41 Mrd. | |
| -0.47% | +4.04% | +23.64% | +13.55% | +15.51% | +54.18% | +11.06% | -6.15% | +151.59% | 14.86 Mrd. | |
| +1.05% | +1.65% | +1.06% | -2.17% | +1.18% | -8.94% | -18.22% | -14.29% | +172.91% | 13.94 Mrd. | |
| -3.72% | +2.49% | -1.92% | +0.49% | -2.44% | +58.06% | +73.87% | +31.43% | +1’159.29% | 13.2 Mrd. | |
| -1.24% | -4.86% | -2.51% | +4.56% | -3.43% | +136.68% | +91.96% | +25.18% | +88.04% | 12.51 Mrd. | |
| +2.53% | +5.04% | +2.20% | -23.52% | +17.88% | +100.32% | - | - | - | 12.26 Mrd. | |
| -2.14% | +4.35% | +19.36% | +11.30% | +16.58% | -9.91% | -15.20% | -22.04% | +233.83% | 10.9 Mrd. | |
| +0.17% | +1.83% | +15.23% | +28.58% | +12.77% | +35.67% | -4.90% | -19.34% | +196.76% | 11 Mrd. | |
| -1.16% | +3.43% | +8.82% | +26.26% | -14.95% | +1’578.69% | +1’364.95% | +202.96% | +667.62% | 9.36 Mrd. | |
| -1.18% | -0.68% | +1.23% | -5.34% | +1.32% | -3.49% | -14.44% | -20.67% | +86.46% | 9.97 Mrd. | |
| +0.14% | -.--% | -.--% | -.--% | -.--% | +23.42% | +170.55% | +28.19% | +632.24% | 8.38 Mrd. | |
| +3.23% | +5.95% | +11.33% | +87.82% | +3.68% | +335.02% | +417.09% | -63.57% | - | 8.26 Mrd. | |
| -2.56% | +2.44% | +10.71% | +1.88% | +12.35% | +27.76% | -36.84% | -42.51% | - | 7.85 Mrd. | |
| Durchschnitt | -0.30% | +0.17% | +15.16% | +25.22% | +10.62% | +1’323.45% | +395.43% | +90.40% | +317.98% | 17.42 Mrd. | |
| Gewichteter Durchschnitt nach Marktkapitalisierung | -0.20% | +1.18% | +15.32% | +23.00% | +12.27% | +1’100.48% | +275.61% | +37.56% | +305.40% |
- Börse
- Aktien
- A0LF18 Aktie
- Sektor Newron Pharmaceuticals S.p.A.
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
MarketScreener is also available in this country: United States.
Switch edition
Bei der aktuellen länderspezifischen Edition bleiben